Proteasomal regulation of caspase-8 in cancer cell apoptosis

Apoptosis

Volumn 18, Issue 6, 2013, Pages 766-776

  Fiandalo, Michael V ^a,b   Schwarze, Steven R ^a   Kyprianou, Natasha ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Caspase 8; Proteasome inhibitors

Indexed keywords

CASPASE 8; GLUTATHIONE TRANSFERASE; PROTEASOME; PROTEASOME INHIBITOR;

APOPTOSIS; ARTICLE; CANCER CELL; CELL ACTIVATION; CELL FRACTIONATION; CELL MIGRATION; CELL VIABILITY; ENZYME ACTIVITY; ENZYME METABOLISM; HUMAN; HUMAN CELL; NEUROBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; UBIQUITINATION;

APOPTOSIS; CASPASE 8; CELL LINE, TUMOR; ENZYME ACTIVATION; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; TNF-RELATED APOPTOSIS-INDUCING LIGAND; UBIQUITINATION;

EID: 84880573790     PISSN: 13608185     EISSN: 1573675X     Source Type: Journal    
DOI: 10.1007/s10495-013-0821-y     Document Type: Article

References (44)

1. Isaacs JT (2000) Apoptosis: translating theory to therapy for prostate cancer. J Natl Cancer Inst 92(17):1367-1369
2. 2+ homeostasis in apoptotic resistance of prostate cancer cells. Biochem Biophys Res Commun 322(4):1326-1335. doi: 10.1016/j.bbrc.2004.08.037
3. Ohtsuka T, Buchsbaum D, Oliver P, Makhija S, Kimberly R, Zhou T (2003) Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22(13):2034-2044. doi: 10.1038/sj.onc.1206290
4. Siu WP, Pun PB, Latchoumycandane C, Boelsterli UA (2008) Bax-mediated mitochondrial outer membrane permeabilization (MOMP), distinct from the mitochondrial permeability transition, is a key mechanism in diclofenac-induced hepatocyte injury: multiple protective roles of cyclosporin A. Toxicol Appl Pharmacol 227(3):451-461. doi: 10.1016/j.taap.2007.11.030
5. Algeciras-Schimnich A, Shen L, Barnhart BC, Murmann AE, Burkhardt JK, Peter ME (2002) Molecular ordering of the initial signaling events of CD95. Mol Cell Biol 22(1):207-220
6. Scott FL, Fuchs GJ, Boyd SE, Denault JB, Hawkins CJ, Dequiedt F, Salvesen GS (2008) Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function. J Biol Chem 283(28):19499-19510. doi: 10.1074/jbc.M800331200
7. Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann TA, DeWolf WC, Khosravi-Far R, Olumi AF (2007) c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res 67(19):9425-9434. doi: 10.1158/0008-5472.CAN-07-1310
8. Diessenbacher P, Hupe M, Sprick MR, Kerstan A, Geserick P, Haas TL, Wachter T, Neumann M, Walczak H, Silke J, Leverkus M (2008) NF-kappaB inhibition reveals differential mechanisms of TNF versus TRAIL-induced apoptosis upstream or at the level of caspase-8 activation independent of cIAP2. J Invest Dermatol 128(5):1134-1147. doi: 10.1038/sj.jid.5701141
9. Medema JP, Scaffidi C, Kischkel FC, Shevchenko A, Mann M, Krammer PH, Peter ME (1997) FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J 16(10):2794-2804. doi: 10.1093/emboj/16.10.2794
10. Krueger A, Schmitz I, Baumann S, Krammer PH, Kirchhoff S (2001) Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem 276(23):20633-20640. doi: 10.1074/jbc.M101780200
11. Scaffidi C, Schmitz I, Krammer PH, Peter ME (1999) The role of c-FLIP in modulation of CD95-induced apoptosis. J Biol Chem 274(3):1541-1548
12. Pop C, Oberst A, Drag M, Van Raam BJ, Riedl SJ, Green DR, Salvesen GS (2011) FLIP(L) induces caspase 8 activity in the absence of interdomain caspase 8 cleavage and alters substrate specificity. Biochem J 433(3):447-457. doi: 10.1042/BJ20101738
13. Wilson TR, McLaughlin KM, McEwan M, Sakai H, Rogers KM, Redmond KM, Johnston PG, Longley DB (2007) c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res 67(12):5754-5762. doi: 10.1158/0008-5472.CAN-06-3585
14. Deveraux QL, Roy N, Stennicke HR, Van Arsdale T, Zhou Q, Srinivasula SM, Alnemri ES, Salvesen GS, Reed JC (1998) IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 17(8):2215-2223. doi: 10.1093/emboj/17.8.2215
15. Casciano I, Banelli B, Croce M, De Ambrosis A, di Vinci A, Gelvi I, Pagnan G, Brignole C, Allemanni G, Ferrini S, Ponzoni M, Romani M (2004) Caspase-8 gene expression in neuroblastoma. Ann N Y Acad Sci 1028:157-167. doi: 10.1196/annals.1322.017
16. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ (2001) Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci USA 98(24):13884-13888. doi: 10.1073/pnas.241358198
17. Cursi S, Rufini A, Stagni V, Condo I, Matafora V, Bachi A, Bonifazi AP, Coppola L, Superti-Furga G, Testi R, Barila D (2006) Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J 25(9):1895-1905. doi: 10.1038/sj.emboj.7601085
18. Jin Z, Li Y, Pitti R, Lawrence D, Pham VC, Lill JR, Ashkenazi A (2009) Cullin3-based polyubiquitination and p62-dependent aggregation of caspase-8 mediate extrinsic apoptosis signaling. Cell 137(4):721-735. doi: 10.1016/j.cell.2009.03.015
19. Peng C, Cho YY, Zhu F, Zhang J, Wen W, Xu Y, Yao K, Ma WY, Bode AM, Dong Z (2011) Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. J Biol Chem 286(9):6946-6954. doi: 10.1074/jbc.M110.172338
20. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP (2001) 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 82(1):110-122
21. Yeung BH, Huang DC, Sinicrope FA (2006) PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem 281(17):11923-11932. doi: 10.1074/jbc.M508533200
22. Crawford LJ, Walker B, Ovaa H, Chauhan D, Anderson KC, Morris TC, Irvine AE (2006) Comparative selectivity and specificity of the proteasome inhibitors BzLLLCOCHO, PS-341, and MG-132. Cancer Res 66(12):6379-6386. doi: 10.1158/0008-5472.CAN-06-0605
23. Balsas P, Lopez-Royuela N, Galan-Malo P, Anel A, Marzo I, Naval J (2009) Cooperation between Apo2L/TRAIL and bortezomib in multiple myeloma apoptosis. Biochem Pharmacol 77(5):804-812. doi: 10.1016/j.bcp.2008.11.024
24. Berkers CR, Verdoes M, Lichtman E, Fiebiger E, Kessler BM, Anderson KC, Ploegh HL, Ovaa H, Galardy PJ (2005) Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods 2(5):357-362. doi: 10.1038/nmeth759
25. Yu C, Rahmani M, Dent P, Grant S (2004) The hierarchical relationship between MAPK signaling and ROS generation in human leukemia cells undergoing apoptosis in response to the proteasome inhibitor Bortezomib. Exp Cell Res 295(2):555-566. doi: 10.1016/j.yexcr.2004.02.001
26. Wang Y, Rishi AK, Puliyappadamba VT, Sharma S, Yang H, Tarca A, Dou QP, Lonardo F, Ruckdeschel JC, Pass HI, Wali A (2010) Targeted proteasome inhibition by Velcade induces apoptosis in human mesothelioma and breast cancer cell lines. Cancer Chemother Pharmacol 66(3):455-466. doi: 10.1007/s00280-009-1181-8
27. Nencioni A, Hua F, Dillon CP, Yokoo R, Scheiermann C, Cardone MH, Barbieri E, Rocco I, Garuti A, Wesselborg S, Belka C, Brossart P, Patrone F, Ballestrero A (2005) Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood 105(8):3255-3262. doi: 10.1182/blood-2004-10- 3984
28. Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM (2009) PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 15(10):3354-3365. doi: 10.1158/1078-0432.CCR-08-2365
29. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 101(6):2377-2380. doi: 10.1182/blood-2002-06- 1768
30. Brooks AD, Jacobsen KM, Li W, Shanker A, Sayers TJ (2010) Bortezomib sensitizes human renal cell carcinomas to TRAIL apoptosis through increased activation of caspase-8 in the death-inducing signaling complex. Mol Cancer Res 8(5):729-738. doi: 10.1158/1541-7786.MCR-10-0022
31. Christian PA, Thorpe JA, Schwarze SR (2009) Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo. Cancer Biol Ther 8(1):73-80
32. Thorpe JA, Christian PA, Schwarze SR (2008) Proteasome inhibition blocks caspase-8 degradation and sensitizes prostate cancer cells to death receptor-mediated apoptosis. Prostate 68(2):200-209. doi: 10.1002/pros.20706
33. Oberst A, Pop C, Tremblay AG, Blais V, Denault JB, Salvesen GS, Green DR (2010) Inducible dimerization and inducible cleavage reveal a requirement for both processes in caspase-8 activation. J Biol Chem 285(22):16632-16642. doi: 10.1074/jbc.M109.095083
34. Chang DW, Xing Z, Capacio VL, Peter ME, Yang X (2003) Interdimer processing mechanism of procaspase-8 activation. EMBO J 22(16):4132-4142. doi: 10.1093/emboj/cdg414
35. Jane EP, Premkumar DR, Pollack IF (2011) Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway. Mol Cancer Ther 10(1):198-208. doi: 10.1158/1535-7163.MCT-10-0725
36. Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, Krupp W, Bauer M, Ahnert P, Meixensberger J, Walczak H (2007) Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 13(11):3403-3412. doi: 10.1158/1078-0432.CCR-07-0251
37. Mitsiades CS, Treon SP, Mitsiades N, Shima Y, Richardson P, Schlossman R, Hideshima T, Anderson KC (2001) TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood 98(3):795-804
38. Sayers TJ, Brooks AD, Koh CY, Ma W, Seki N, Raziuddin A, Blazar BR, Zhang X, Elliott PJ, Murphy WJ (2003) The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL-mediated apoptosis by reducing levels of c-FLIP. Blood 102(1):303-310. doi: 10.1182/blood-2002-09-2975
39. Plasilova M, Zivny J, Jelinek J, Neuwirtova R, Cermak J, Necas E, Andera L, Stopka T (2002) TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia 16(1):67-73. doi: 10.1038/sj.leu.2402338
40. Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z, Lynch PM, Moyer MP, Wen XF, Wu X (2010) Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature 464(7291):1058-1061. doi: 10.1038/nature08871
41. Li W, Zhang X, Olumi AF (2007) MG-132 sensitizes TRAIL-resistant prostate cancer cells by activating c-Fos/c-Jun heterodimers and repressing c-FLIP(L). Cancer Res 67(5):2247-2255. doi: 10.1158/0008-5472.CAN-06-3793
42. Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY (2007) The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells. Cancer Res 67(10):4981-4988. doi: 10.1158/0008-5472.CAN-06-4274
43. Martin DA, Siegel RM, Zheng L, Lenardo MJ (1998) Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. J Biol Chem 273(8):4345-4349
44. Christian PA, Fiandalo MV, Schwarze SR (2011) Possible role of death receptor-mediated apoptosis by the E3 ubiquitin ligases Siah2 and POSH. Mol Cancer 10:57. doi: 10.1186/1476-4598-10-57